Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Elixiron Immunotherapeutics (Hong Kong) Limited manages 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are spread across 2 distinct examiners but are contained within 1 distinct art unit. This suggests that while the technical focus is narrow, the USPTO has assigned multiple reviewers to the company's applications. This distribution can lead to different prosecution paces even within the same art unit, as each examiner may have different internal workloads and response times.
The busiest examiner, PRIEST, JESSICA MARIE, is responsible for 1 busiest examiner pending office action. This figure is part of the 2 pending office actions currently active for the portfolio. The distribution of 1 action per examiner across 2 distinct examiners indicates a balanced workload distribution within the single art unit involved. For practitioners, this means that while the technical subject matter remains consistent, they must adapt their advocacy to the specific preferences and tendencies of 2 distinct examiners simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PRIEST, JESSICA MARIE | 1 | — | — |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18519188 | ENGINEERED INTERLEUKIN-10 AND FUSION PROTEINS THEREOF | PRIEST, JESSICA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18478363 | ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18519188 | ENGINEERED INTERLEUKIN-10 AND FUSION PROTEINS THEREOF | PRIEST, JESSICA MARIE | 1642 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18478363 | ANTI-PD-L1 ANTIBODIES AND ANTI-PD-L1/IL10 FUSION PROTEINS | OUSPENSKI, ILIA I | — | DP | Non-Final OA | — | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial